Drug Pricing Reform In US: It’s Over For 2017
There's lots of buzz about drug pricing actions, be they executive or legislative. But the die is cast for this year: real reforms will have to wait.
You may also be interested in...
As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.
Hearings in July and the fall will follow, but if the first session was any indication, industry doesn't have anything to worry about.
Energy and Commerce Committee leadership requests audit records and other documents from the Health Resources and Services Administration to evaluate the effectiveness of its oversight of the program.